Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03516279
Title Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ECOG-ACRIN Cancer Research Group
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.